[{"from": "human", "value": "Please give me some details about this molecule. [C][=C][C][=Branch1][C][=O][N][C][C][C][C@H1][Branch1][Ring2][C][Ring1][=Branch1][N][C][=N][C][=N][C][=Branch2][Ring1][=N][=C][Ring1][=Branch1][C][=Branch1][Ring2][=N][Ring1][=Branch2][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][=C][C][=C][C][=C][Ring1][=Branch1][N]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival."}]